Vutrisiran: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Add: s2cid. | Use this bot. Report bugs. | Suggested by Abductive | Category:Chemicals using indexlabels | #UCB_Category 35/675 |
|||
| Line 103: | Line 103: | ||
}} |
}} |
||
'''Vutrisiran''', sold under the brand name '''Amvuttra''', is a [[medication]] used for the treatment of the [[polyneuropathy]] of [[hereditary transthyretin-mediated amyloidosis|hereditary transthyretin-mediated (hATTR) amyloidosis]] in adults.<ref name="Alnylam PR 20220613" /> It is a [[small interfering RNA]] (siRNA) that interferes with the expression of the [[transthyretin]] (TTR) gene.<ref name="Aimo_2022">{{cite journal | vauthors = Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M | title = RNA-targeting and gene editing therapies for transthyretin amyloidosis | journal = Nature Reviews. Cardiology | volume = | issue = | pages = | date = March 2022 | pmid = 35322226 | doi = 10.1038/s41569-022-00683-z }}</ref> |
'''Vutrisiran''', sold under the brand name '''Amvuttra''', is a [[medication]] used for the treatment of the [[polyneuropathy]] of [[hereditary transthyretin-mediated amyloidosis|hereditary transthyretin-mediated (hATTR) amyloidosis]] in adults.<ref name="Alnylam PR 20220613" /> It is a [[small interfering RNA]] (siRNA) that interferes with the expression of the [[transthyretin]] (TTR) gene.<ref name="Aimo_2022">{{cite journal | vauthors = Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M | title = RNA-targeting and gene editing therapies for transthyretin amyloidosis | journal = Nature Reviews. Cardiology | volume = | issue = | pages = | date = March 2022 | pmid = 35322226 | doi = 10.1038/s41569-022-00683-z | s2cid = 247623259 }}</ref> |
||
Vutrisiran was approved for medical use in the United States in June 2022.<ref name="Alnylam PR 20220613" /> |
Vutrisiran was approved for medical use in the United States in June 2022.<ref name="Alnylam PR 20220613" /> |
||
Revision as of 06:48, 1 July 2022
| Clinical data | |
|---|---|
| Trade names | Amvuttra |
| Other names | ALN-65492 |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| UNII |
|
| KEGG | |
Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.[1] It is a small interfering RNA (siRNA) that interferes with the expression of the transthyretin (TTR) gene.[3]
Vutrisiran was approved for medical use in the United States in June 2022.[1]
Vutrisiran is the international nonproprietary name (INN).[4]
History
The U.S. Food and Drug Administration (FDA) granted the application for vutrisiran orphan drug designation.[5]
References
- ^ a b c "Alnylam Announces FDA Approval of Amvuttra (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults". Alnylam. 13 June 2022. Archived from the original on 14 June 2022. Retrieved 14 June 2022 – via Business Wire.
- ^ "AMVUTTRA (vutrisiran) prescribing information" (PDF). Cambridge, MA: Alnylam Pharmaceuticals, Inc. June 2022. Archived (PDF) from the original on 14 June 2022. Retrieved 14 June 2022.
- ^ Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M (March 2022). "RNA-targeting and gene editing therapies for transthyretin amyloidosis". Nature Reviews. Cardiology. doi:10.1038/s41569-022-00683-z. PMID 35322226. S2CID 247623259.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
- ^ "Vutrisiran Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 25 May 2018. Retrieved 14 June 2022.
External links
- "Vutrisiran". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |